Literature DB >> 22751340

Thyroid cancer: successful remnant ablation-what is success?

Thera P Links, Anouk N A van der Horst-Schrivers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22751340     DOI： 10.1038/nrendo.2012.113

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

2.  The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

Authors:  Tae Hyuk Kim; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; You Jin Lee; Kyung Won Kim; Seo Kyung Hahn; Yeo Kyu Youn; Kwang Hyun Kim; Bo Youn Cho; Do Joon Park
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

3.  Treatment of thyroid cancer. Death rates after surgery and after surgery followed by sodium iodide I-131.

Authors:  V M Varma; W H Beierwaltes; M M Nofal; R H Nishiyama; J E Copp
Journal:  JAMA       Date:  1970-11-23       Impact factor: 56.272

Review 4.  131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review.

Authors:  Allan Hackshaw; Clive Harmer; Ujjal Mallick; Masud Haq; Jayne A Franklyn
Journal:  J Clin Endocrinol Metab       Date:  2006-10-10       Impact factor: 5.958

5.  Strategies of radioiodine ablation in patients with low-risk thyroid cancer.

Authors:  Martin Schlumberger; Bogdan Catargi; Isabelle Borget; Désirée Deandreis; Slimane Zerdoud; Boumédiène Bridji; Stéphane Bardet; Laurence Leenhardt; Delphine Bastie; Claire Schvartz; Pierre Vera; Olivier Morel; Danielle Benisvy; Claire Bournaud; Françoise Bonichon; Catherine Dejax; Marie-Elisabeth Toubert; Sophie Leboulleux; Marcel Ricard; Ellen Benhamou
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

6.  Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

Authors:  Ujjal Mallick; Clive Harmer; Beng Yap; Jonathan Wadsley; Susan Clarke; Laura Moss; Alice Nicol; Penelope M Clark; Kate Farnell; Ralph McCready; James Smellie; Jayne A Franklyn; Rhys John; Christopher M Nutting; Kate Newbold; Catherine Lemon; Georgina Gerrard; Abdel Abdel-Hamid; John Hardman; Elena Macias; Tom Roques; Stephen Whitaker; Rengarajan Vijayan; Pablo Alvarez; Sandy Beare; Sharon Forsyth; Latha Kadalayil; Allan Hackshaw
Journal:  N Engl J Med       Date:  2012-05-03       Impact factor: 91.245

7.  Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis.

Authors:  T P Links; K M van Tol; P L Jager; J Th M Plukker; D A Piers; H M Boezen; R P F Dullaart; E G E de Vries; W J Sluiter
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

8.  The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation.

Authors:  Ha T T Phan; Pieter L Jager; Jacqueline E van der Wal; Wim J Sluiter; John T M Plukker; Rudi A J O Dierckx; Bruce H R Wolffenbuttel; Thera P Links
Journal:  Eur J Endocrinol       Date:  2008-01       Impact factor: 6.664

9.  Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.

Authors:  Furio Pacini; Eleonora Molinaro; Maria Grazia Castagna; Francesco Lippi; Claudia Ceccarelli; Laura Agate; Rossella Elisei; Aldo Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2002-09       Impact factor: 5.958

10.  Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study.

Authors:  Hanna O Mäenpää; Jorma Heikkonen; Leila Vaalavirta; Mikko Tenhunen; Heikki Joensuu
Journal:  PLoS One       Date:  2008-04-02       Impact factor: 3.240
  10 in total
  4 in total

Review 1.  Radioiodine therapy for patients with differentiated thyroid cancer after thyroidectomy: direct comparison and network meta-analyses.

Authors:  Y Fang; Y Ding; Q Guo; J Xing; Y Long; Z Zong
Journal:  J Endocrinol Invest       Date:  2013-05-30       Impact factor: 4.256

2.  Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study.

Authors:  Anouk N A van der Horst-Schrivers; Wim J Sluiter; Anneke C Muller Kobold; Bruce H R Wolffenbuttel; John T M Plukker; Peter H Bisschop; John M de Klerk; Imad Al Younis; Paul Lips; Jan W Smit; Adrienne H Brouwers; Thera P Links
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

3.  Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.

Authors:  Hakim-Moulay Dehbi; Ujjal Mallick; Jonathan Wadsley; Kate Newbold; Clive Harmer; Allan Hackshaw
Journal:  Lancet Diabetes Endocrinol       Date:  2018-11-27       Impact factor: 32.069

4.  Strong Neck Accumulation of 131I Is a Predictor of Incomplete Low-Dose Radioiodine Remnant Ablation Using Recombinant Human Thyroid-Stimulating Hormone.

Authors:  Keisuke Enomoto; Yoshiharu Sakata; Kazuyuki Izumi; Yukinori Takenaka; Miki Nagai; Kazuya Takeda; Yukie Enomoto; Atsuhiko Uno
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.